NuCana Stock Surges 185% on Promising Melanoma Treatment ResultsNuCana plc (NASDAQ: NASDAQ:NCNA ) saw its stock skyrocket by 185% after presenting final data from its Phase 2 NuTide:701 study at the European Society for Medical Oncology (ESMO) Congress. This significant surge comes after a tough stretch for the company, especially following disappointing result
